1Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes , heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood, 2002, 99(9): 3256-3262.
2Manches 0, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood, 2003,101(3): 949-954.
3Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol , 2010, 47(2): 107-114.
4Miszlai Z, Czink E, Varga L, et al. Repressed classical complement pathway activities and clinical correlations in chronic lymphocytic leukaemia. Acta Med Hung, 1986,43(4): 389-395.
5Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol , 2004, 172 (5): 3280- 3288.
6Klepfish A, Rachmilewitz EA, Kotsianidis 1, et al. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM, 2008, 101(9): 737-740.
7Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement?mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by acaspase?independent mechanism involving the generation of reactive oxygen species. Blood, 2001, 98(9): 2771-2777.
8Williams ME, Densmore JJ, Pawluczkowycz A W, et al. Thrice?weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol , 2006, 177(10): 7435-7443.
9Jilani I, 0' Brien S, Manshuri T, et al. Transient down?modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood, 2003, 102(10): 3514-3520.
10Beum PV, Peek EM, Lindorfer MA, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fe receptor-expressing effector cells than direct internalization by the B cells. J Immunol , 2011, 187(6): 3438-3447.
